loader2
Partner With Us NRI

Medicamen Biotech Ltd share Price Today

Company details

479.00
487.75
355.45
845.00
6M Return -19.13%
1Y Return -27.66%
Mkt Cap.(Cr) 606.36
Volume 8,184
Div Yield 0.21%
OI
-
OI Chg %
-
Volume 8,184

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Medicamen Biotech Ltd shares SWOT Analysis

Strengths (7)

  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with Low Debt
  • Increasing Revenue every Quarter for the past 4 Quarters

Weakness (8)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (0)

Data not found

Threats (1)

  • High PE (PE > 40)

Resistance and support

R1 485.5
R2 491.4
R3 496.0
Pivot

480.85

S1 474.9
S2 470.3
S3 464.4
EMA SMA
491.0
489.0
503.3
551.6
501.1
480.8
484.8
560.1
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SHIVALIK RASAYAN LIMITED Bulk Purchase 2024-03-22 421.86 200000 NSE
GROWEL REMEDIES LIMITED Bulk Sell 2024-03-22 421.86 200000 NSE
JMP SECURITIES PVT LTD Bulk Purchase 2016-11-16 250.96 55011 BSE
Name Category Shares
Shivalik Rasayan Limited PROMOTER 43.21%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Medicamen Biotech Ltd Stocks COMPARISON

Financials( in Cr) Medicamen Biotech Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 479.30 1,510.40 1,544.15 4,589.00 1,089.00
% Change -0.04 0.24 0.21 3.07 -0.72
Mcap Cr 606.36 362,395.56 124,669.58 121,823.72 109,578.88
Revenue TTM Cr 140.87 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 14.73 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 55.58 36.10 29.21 73.81 28.64
1 Year Return -27.66 53.27 60.86 33.46 113.53
ROCE 10.36 16.79 14.76 19.30 16.25
ROE 8.67 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 190.81 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 34,884.91 -9,332.45
LAST 3M 106,892.87 -46,178.73
LAST 6M 180,013.62 -16,713.35
LAST 12M 285,796.32 100,710.28

Medicamen Biotech Ltd Information

Stock PE (TTM)
55.58
Promoter Holding
43.21%
Book Value
158.4219
ROCE
10.36%
ROE
8.67%
Description
  • Medicamen Biotech Ltd is a widely held, Globally Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. The company is engaged in manufacture and distribution of medicines. They manufacturer and supply the range of products such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non beta lactum) and ointment. The company has two manufacturing facilities namely, Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures Non-Betalactum preparations including tablets, capsules, oral liquids and ointments & creams. The company is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical Fraternity. Medicamen Biotech Ltd was incorporated on December 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries. The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange. In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitment. During the year 2006-07, the company added Analgesic and Anti bacterial, Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year, the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos. The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets, Capsules, oral liquids & ointments with the production capacity of 4100 lakh Nos, 600 lakh Nos, 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.` The Company launched the marketing division in Jan`09, with 16 products in Delhi & Uttrakhand regions. On September 16, 2015, M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company - SPA 1 with Mr. Bal Kishan Gupta, Mr. Ashutosh Gupta, Ms. Ritu Gupta, Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal, Ms. Manju Bansal, Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 44,12,095 fully paid-up Equity Shares of Rs.10/- each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company, which was completed in December, 2015 and the Acquirer became New Promoter of the Company. The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) $4,20,000 in 2019-20. OPAL, a wholly owned subsidiary of the Company, merged with the Company effective September 17, 2019. The Company has launched 12 Oncology products in domestic market effective from January, 2022.

Registered Address

1506 Chiranjiv Tower 43, Nehru Place, New Delhi, New Delhi, 110019

Tel : 91-11-47589500
Email : cs:medicamen.com
Website : http://www.medicamen.com
Registrar

Intime Spectrum Registry Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 531146
NSE Code : MEDICAMEQ
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE646B01010

FAQ’s on Medicamen Biotech Ltd Shares

You can buy Medicamen Biotech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Medicamen Biotech Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 13, 2024 03:09 PM the closing price of Medicamen Biotech Ltd was Rs.479.30.

The latest PE ratio of Medicamen Biotech Ltd as of Jun 13, 2024 03:09 PM is 55.58

The latest PB ratio of Medicamen Biotech Ltd as of Jun 13, 2024 03:09 PM is 0.33

The 52-week high of Medicamen Biotech Ltd share price is Rs. 845.00 while the 52-week low is Rs. 355.45

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 13, 2024 03:09 PM, the market cap of Medicamen Biotech Ltd stood at Rs. 606.36.

Download App

Download Our App

Play Store App Store
market app